InvivoSciences

InvivoSciences, Inc. (IVS) is a pre-clinical-stage biotech company developing therapies for cardiovascular and cardiometabolic diseases. Its innovation is utilizing its predictive precision medicine development technology platform, Kokordia, combining patient-derived micro heart on a chip, NuHeart, AI-assisted patient-stratification diagnostic technology, and automated instrumentation for precision medicine development. IVS201 is its lead program targeting heart failure with preserved ejection fraction (HFpEF). Heart failure (HF), such as HFpEF, is a complex disease with different subgroups, where patient stratification is the key to advancing a targeted therapy in every challenging HF drug development.

The company's first pipeline, IVS201, is a repurposed drug candidate for treating a rare form of HFpEF, defined by its AI-assisted patient stratification technology. The platform technology discovered IVS201, and it has existing clinical safety data, including oral administration dosing. IVS201 targets interstitial cardiac fibrosis to relieve diastolic stiffness without affecting cardiac contractility. The genetic and biochemical analysis validated that the target protein silencing reversed the fibrotic phenotype (e.g., extracellular protein expression). The AI-assisted diagnostic technology stratifies HFpEF patients with functional data, which will be used to monitor the efficacy of IVS201. Quantitative functional endpoints can drastically reduce clinical trial time and sample size, revolutionizing the productivity of HF clinical trials. Our patient data analysis has been expanded to identify candidate cohorts for IVS201.